Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Global pharma shares slide as Biden backs COVID-19 vaccine IP waiver

Published 2021-05-06, 05:39 a/m
Updated 2021-05-06, 07:12 a/m
© Reuters. FILE PHOTO: A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine"  in this illustration

By Julien Ponthus

(Reuters) - Shares of drugmakers involved in the production of COVID-19 vaccines, including Pfizer (NYSE:PFE) and Moderna, fell on Thursday, a day after U.S. President Joe Biden's plan to back intellectual property waivers on vaccines.

Biden threw his support behind a World Trade Organization waiver of intellectual property rights on vaccines to increase their availability to poorer nations including India, which is under the grip of a massive second wave of infection.

Implementing such a move could be a lengthy process, with all 164 WTO member countries required to arrive at a consent, but it could dent revenue and profit for companies that have invested heavily in the vaccines..

"It could clearly reduce potential revenues some of these firms were expecting to generate from licensing their patents", said Neil Wilson, chief market analyst at Markets.com.

Shares of Pfizer, Moderna, Novavax and U.S. shares of BioNTech were all down between 2% and 6% before the bell. BioNTech's Frankfurt-listed shares fell as much as 19% and were down 13% by 1029 GMT.

Pharma shares lost ground elsewhere too, with Germany's Curevac, which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.

Shares in Chinese vaccine makers slumped with CanSino Biologics Inc, a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares dived as much as 22%.

However, shares in London-listed AstraZeneca (NASDAQ:AZN) were unchanged however. Europe's index of healthcare stocks was down 0.5%, slightly lagging the pan-European STOXX 600 benchmark.

Jefferies analyst Michael Yee said any suggestion that other countries could just manufacture and override patents will likely decrease investor confidence in the business models during a pandemic.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Yee, however, cautioned that manufacturing supplies, raw materials, vials, stoppers, and other key materials are in limited supply for 2021 to matter for the ongoing situation in India and South Africa.

For a graphic on Curevac:

https://fingfx.thomsonreuters.com/gfx/mkt/jbypryjgzve/Pasted%20image%201620291460919.png

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.